Axsome Therapeutics Provides Preliminary Fourth Quarter and Full …

1 day ago · Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by …

$92
OFF

Axsome Therapeutics Provides Preliminary Fourth Quarter And Full …

2 weeks from now

2 days ago · Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively Sunosi preliminary 4Q and full year 2024 net product revenue of …

businessinsider.com

$140
OFF

Axsome Therapeutics Price Target Raised To $140 From $138 At RBC ...

2 weeks from now

Jan 7, 2025 · RBC Capital raised the firm’s price target on Axsome Therapeutics (AXSM) to $140 from $138 and keeps an Outperform rating on the shares as part of a broader research note …

nasdaq.com

7%
OFF

Axsome (AXSM) Stock Rises On Stellar Q4 Preliminary Results

2 weeks from now

Jan 5, 2024 · Shares of Axsome Therapeutics, Inc. AXSM were up 7.7% on Jan 4 after the company announced robust preliminary results for the fourth quarter and full-year 2023. …

nasdaq.com

85%
OFF

TD Cowen Keeps Their Buy Rating On Axsome Therapeutics (AXSM)

2 weeks from now

Dec 30, 2024 · The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axsome Therapeutics with a $134.36 average price target, a 63.85% upside from …

businessinsider.com

$1.34
OFF

Axsome Therapeutics (NASDAQ:AXSM) Earns "Buy" Rating From …

2 weeks from now

Jan 6, 2025 · Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, …

marketbeat.com

FAQs about Axsome Therapeutics Provides Preliminary Fourth Quarter and Full … Coupon?

Is Axsome Therapeutics (AXSM) a good stock to buy?

According to 13 Wall Street equities research analysts, the consensus is that investors should moderate buy Axsome Therapeutics (AXSM) shares. There are currently 1 hold rating and 12 buy ratings for the stock. ...

How much revenue did Axsome Therapeutics earn in the quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced its quarterly earnings results on Monday, May, 6th. The company earned $75 million during the quarter, compared to analysts' expectations of $69.91 million. The company reported ($1.09) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.11. ...

How much money does Axsome Therapeutics make a year?

Axsome Therapeutics (NASDAQ:AXSM) has a recorded annual revenue of $50.04 million. How much profit does Axsome Therapeutics generate each year? Axsome Therapeutics (NASDAQ:AXSM) has a recorded net income of -$187.13 million. AXSM has generated -$3.80 earnings per share over the last four quarters. ...

What does Axsome Therapeutics Inc (axsm) do?

The Company focuses on developing therapies for pain, neurological disorders, and other central nervous system. Axsome Therapeutics serves patients worldwide. Stock analysis for Axsome Therapeutics Inc (AXSM:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. ...

How did Axsome Therapeutics (axsm) perform in the quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced its quarterly earnings results on Monday, May 6th. The company reported ($1.09) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.11. The company earned $75 million during the quarter, compared to analysts' expectations of $69.91 million. ...

When is Axsome Therapeutics's next earnings report?

Axsome Therapeutics has confirmed that its next quarterly earnings report will be published on Monday, August 7th, 2023. Axsome Therapeutics will be holding an earnings conference call on Monday, August 7th at 8:00 AM Eastern. Interested parties can register for or listen to the call.. When is Axsome Therapeutics's earnings date? ...